FDA Approves VANRAFIA, Disrupting IgA Nephropathy Market
VANRAFIA (atrasentan), FDA-approved in April 2025, showed strong proteinuria reduction without REMS but carries similar safety warnings, requiring ongoing liver and pregnancy monitoring. However, its approval...